Foster & Motley Inc. Trims Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Foster & Motley Inc. trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,409 shares of the medical equipment provider’s stock after selling 473 shares during the period. Foster & Motley Inc.’s holdings in Zimmer Biomet were worth $293,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Schechter Investment Advisors LLC lifted its holdings in Zimmer Biomet by 21.6% in the 3rd quarter. Schechter Investment Advisors LLC now owns 4,241 shares of the medical equipment provider’s stock valued at $476,000 after purchasing an additional 752 shares in the last quarter. Atria Wealth Solutions Inc. lifted its holdings in shares of Zimmer Biomet by 5.9% during the 3rd quarter. Atria Wealth Solutions Inc. now owns 20,566 shares of the medical equipment provider’s stock worth $2,312,000 after acquiring an additional 1,144 shares during the period. International Assets Investment Management LLC lifted its holdings in shares of Zimmer Biomet by 11,244.9% during the 4th quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider’s stock worth $8,146,000 after acquiring an additional 66,345 shares during the period. Amalgamated Bank lifted its holdings in shares of Zimmer Biomet by 3.0% during the 3rd quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider’s stock worth $6,303,000 after acquiring an additional 1,631 shares during the period. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of Zimmer Biomet by 37.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider’s stock worth $18,981,000 after acquiring an additional 42,539 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Down 0.3 %

Shares of NYSE:ZBH opened at $121.17 on Thursday. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. The company has a fifty day simple moving average of $126.18 and a 200 day simple moving average of $119.46. The firm has a market cap of $24.90 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 2.23 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.00 and a 12-month high of $149.25.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The business had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. During the same quarter in the previous year, the firm earned $1.88 earnings per share. The business’s revenue was up 6.3% compared to the same quarter last year. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.79%. Zimmer Biomet’s payout ratio is 19.63%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares in the company, valued at $5,677,929.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.95% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ZBH. Barclays increased their price objective on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a report on Monday, February 12th. Truist Financial lifted their price target on shares of Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a research report on Friday, February 9th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a research report on Friday, February 23rd. TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research report on Thursday, February 8th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $139.39.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.